It was found that the growth of Lgr5+ cells can be controlled by PTEN/AKT and Wnt/β-catenin pathways, and Lgr5 has emerged as a potential therapeutic target for the treatment of hepatocellular carcinoma [48,49]. This evidence concerns the gene AKT1 and hepatocellular carcinoma.